FRET-Based detection of M 1 muscarinic acetylcholine receptor activation by orthosteric and allosteric agonists

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Markovic, Danijela ^a,f   Holdich, Jonathan ^b   Al Sabah, Suleiman ^c,d   Mistry, Rajendra ^a   Krasel, Cornelius ^c,e   Mahaut Smith, Martyn P ^a,b   Challiss, R A John ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF READING   (United Kingdom)

^d KUWAIT UNIVERSITY   (Kuwait)

^e Institut für Pharmakologie and Toxikologie   (Germany)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

77 LH 28 1; AC 42; ARECOLINE; ATROPINE; CYAN FLUORESCENT PROTEIN; G PROTEIN COUPLED RECEPTOR; METHACHOLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M1 RECEPTOR ALLOSTERIC AGONIST; MUSCARINIC M1 RECEPTOR ORTHOSTERIC AGONIST; PHOSPHATIDYLINOSITIDE; PILOCARPINE; PROTEIN VARIANT; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN; 4 N BUTYL 1 (4 (2 METHYLPHENYL) 4 OXO 1 BUTYL) PIPERIDINE HYDROGEN CHLORIDE; 4-N-BUTYL-1-(4-(2-METHYLPHENYL)-4-OXO-1-BUTYL)-PIPERIDINE HYDROGEN CHLORIDE; HYBRID PROTEIN; METHACHOLINE CHLORIDE; MUSCARINIC AGENT; PHOTOPROTEIN; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EVOKED RESPONSE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; INTERNALIZATION; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; WILD TYPE; ANIMAL; BINDING COMPETITION; CONFOCAL MICROSCOPY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GENETIC TRANSFECTION; GENETICS; KINETICS; METABOLISM; METHODOLOGY;

ANIMALS; ARECOLINE; ATROPINE; BINDING, COMPETITIVE; CELL MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELLS; HUMANS; KINETICS; LUMINESCENT PROTEINS; MALE; METHACHOLINE CHLORIDE; MICE; MICROSCOPY, CONFOCAL; MUSCARINIC AGONISTS; PIPERIDINES; RECEPTOR, MUSCARINIC M1; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 84855830609     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029946     Document Type: Article

References (40)

1. Caulfield MP, Birdsall NJ, (1998) International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50: 279-290.
2. Challiss RAJ, Thomas RL, (2009) Signaling diversity mediated by muscarinic acetylcholine receptor subtypes and evidence for functional selectivity. In: Neve KA, editors. Functional selectivity of G protein-coupled receptor ligands Humana Press pp. 125-154.
3. Wess J, Eglen RM, Gautam D, (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6: 721-733.
4. Langmead CJ, Watson J, Reavill C, (2008) Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 117: 232-243.
5. Birdsall NJ, Lazareno S, (2005) Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5: 523-543.
6. Conn PJ, Jones CK, Lindsley CW, (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 30: 148-155.
7. Bonner TI, Young AC, Brann MR, Buckley NJ, (1988) Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1: 403-410.
8. Lu ZL, Saldanha JW, Hulme EC, (2002) Seven-transmembrane receptors: crystals clarify. Trends Pharmacol Sci 23: 140-146.
9. Spalding TA, Burstein ES, Henderson SC, Ducote KR, Brann MR, (1998) Identification of a ligand-dependent switch within a muscarinic receptor. J Biol Chem 273: 21563-21568.
10. Hulme EC, Lu ZL, Bee MS, (2003) Scanning mutagenesis studies of the M1 muscarinic acetylcholine receptor. Receptors Channels 9: 215-228.
11. Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, et al. (2006) Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol Pharmacol 70: 1974-1983.
12. Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, et al. (2008) Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol 154: 1104-1115.
13. Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, et al. (2009) Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol 75: 577-588.
14. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, et al. (2002) Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol Pharmacol 61: 1297-1302.
15. Lebon G, Langmead CJ, Tehan BG, Hulme EC, (2009) Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol Pharmacol 75: 331-341.
16. Vilardaga JP, Bünemann M, Krasel C, Castro M, Lohse MJ, (2003) Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat Biotechnol 21: 807-812.
17. Lohse MJ, Nikolaev VO, Hein P, Hoffmann C, Vilardaga JP, et al. (2008) Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors. Trends Pharmacol Sci 29: 159-165.
18. Rizzo MA, Springer GH, Granada B, Piston DW, (2004) An improved cyan fluorescent protein variant useful for FRET. Nat Biotechnol 22: 445-449.
19. Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, et al. (2002) A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol 20: 87-90.
20. Thomas RL, Mistry R, Langmead CJ, Wood MD, Challiss RAJ, (2008) G protein coupling and signaling pathway activation by M1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther 327: 365-374.
21. Markovic D, Punn A, Lehnert H, Grammatopoulos DK, (2008) Intracellular mechanisms regulating corticotropin-releasing hormone receptor-2β endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades. Mol Endocrinol 22: 689-706.
22. Krasel C, Zabel U, Lorenz K, Reiner S, Al-Sabah S, et al. (2008) Dual role of the β2-adrenergic receptor C-terminus for the binding of β-arrestin and receptor internalization. J Biol Chem 283: 31840-31848.
23. Kaye RG, Saldanha JW, Lu ZL, Hulme EC, (2011) Helix 8 of the M1 muscarinic acetylcholine receptor: scanning mutagenesis delineates a G protein recognition site. Mol Pharmacol 79: 701-709.
24. Goldman PS, Schlador ML, Shapiro RA, Nathanson NM, (1996) Identification of a region required for subtype-specific agonist-induced sequestration of the m2 muscarinic acetylcholine receptor. J Biol Chem 271: 4215-4222.
25. Shockley MS, Tolbert LM, Tobin AB, Nahorski SR, Sadée W, et al. (1999) Differential regulation of muscarinic M1 and M3 receptors by a putative phosphorylation domain. Eur J Pharmacol 377: 137-146.
26. Sawyer GW, Ehlert FJ, Shults CA, (2008) Cysteine pairs in the third intracellular loop of the muscarinic m1 acetylcholine receptor play a role in agonist-induced internalization. J Pharmacol Exp Ther 324: 196-205.
27. Thomas RL, Mistry R, Langmead CJ, Wood MD, Challiss RAJ, (2008) G protein coupling and signaling pathway activation by M1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther 327: 365-374.
28. Jensen JB, Lyssand JS, Hague C, Hille B, (2009) Fluorescence changes reveal kinetic steps of muscarinic receptor-mediated modulation of phosphoinositides and Kv7.2/7.3 K+ channels. J Gen Physiol 133: 347-359.
29. Falkenburger BH, Jensen JB, Hille B, (2010) Kinetics of M1 muscarinic receptor and G protein signaling to phospholipase C in living cells. J Gen Physiol 135: 81-97.
30. Ziegler N, Bätz J, Zabel U, Lohse MJ, Hoffmann C, (2011) FRET-based sensors for the human M1-, M3-, and M5-acetylcholine receptors. Bioorg Med Chem 19: 1048-1054.
31. Hoffmann C, Gaietta G, Bünemann M, Adams SR, Oberdorff-Maass S, et al. (2005) A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat Methods 2: 171-176.
32. Chachisvilis M, Zhang YL, Frangos JA, (2006) G protein-coupled receptors sense fluid shear stress in endothelial cells. Proc Natl Acad Sci USA 103: 15463-15468.
33. Nikolaev VO, Hoffmann C, Bünemann M, Lohse MJ, Vilardaga JP, (2006) Molecular basis of partial agonism at the neurotransmitter α2A-adrenergic receptor and Gi-protein heterotrimer. J Biol Chem 281: 24506-24511.
34. Maier-Peuschel M, Frölich N, Dees C, Hommers LG, Hoffmann C, et al. (2010) A fluorescence resonance energy transfer-based M2 muscarinic receptor sensor reveals rapid kinetics of allosteric modulation. J Biol Chem 285: 8793-8800.
35. Vilardaga JP, Steinmeyer R, Harms GS, Lohse MJ, (2005) Molecular basis of inverse agonism in a G protein-coupled receptor. Nat Chem Biol 1: 25-28.
36. Zürn A, Zabel U, Vilardaga JP, Schindelin H, Lohse MJ, et al. (2009) Fluorescence resonance energy transfer analysis of α2A-adrenergic receptor activation reveals distinct agonist-specific conformational changes. Mol Pharmacol 75: 534-541.
37. Zhang YL, Frangos JA, Chachisvilis M, (2009) Mechanical stimulus alters conformation of type 1 parathyroid hormone receptor in bone cells. Am J Physiol 296: C1391-C1399.
38. Daeffler L, Schmidlin F, Gies JP, Landry Y, (1999) Inverse agonist activity of pirenzepine at M2 muscarinic acetylcholine receptors. Br J Pharmacol 126: 1246-1252.
39. Nelson CP, Nahorski SR, Challiss RAJ, (2006) Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. J Pharmacol Exp Ther 316: 279-288.
40. Dowling MR, Willets JM, Budd DC, Charlton SJ, Nahorski SR, et al. (2006) A single point mutation (N514Y) in the human M3 muscarinic acetylcholine receptor reveals differences in the properties of antagonists: evidence for differential inverse agonism. J Pharmacol Exp Ther 317: 1134-1142.